In conclusion, though the degree of benefit from a single treatment timepoint greatly varies among different cell lines, reducing PIK3C2A mRNA levels sensitized HNSCC cell lines to EGFR inhibition with gefitinib. This evidence concerns the gene PIK3C2A and head and neck squamous cell carcinoma.